These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

630 related items for PubMed ID: 15817798

  • 1. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
    Wharton J, Strange JW, Møller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR.
    Am J Respir Crit Care Med; 2005 Jul 01; 172(1):105-13. PubMed ID: 15817798
    [Abstract] [Full Text] [Related]

  • 2. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells.
    Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, Branzi A, Galié N.
    Basic Res Cardiol; 2005 Mar 01; 100(2):131-8. PubMed ID: 15739122
    [Abstract] [Full Text] [Related]

  • 3. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle.
    Park K, Moreland RB, Goldstein I, Atala A, Traish A.
    Biochem Biophys Res Commun; 1998 Aug 28; 249(3):612-7. PubMed ID: 9731184
    [Abstract] [Full Text] [Related]

  • 4. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
    Thelitz S, Bekker JM, Ovadia B, Stuart RB, Johengen MJ, Black SM, Fineman JR.
    J Thorac Cardiovasc Surg; 2004 May 28; 127(5):1285-92. PubMed ID: 15115984
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy.
    Rondelet B, Kerbaul F, Van Beneden R, Motte S, Fesler P, Hubloue I, Remmelink M, Brimioulle S, Salmon I, Ketelslegers JM, Naeije R.
    Circulation; 2004 Oct 12; 110(15):2220-5. PubMed ID: 15466636
    [Abstract] [Full Text] [Related]

  • 7. Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway.
    Moreno L, Losada B, Cogolludo Al, Lodi F, Lugnier C, Villamor E, Moro M, Tamargo J, Pérez-Vizcaíno F.
    Pediatr Res; 2004 Oct 12; 56(4):563-70. PubMed ID: 15295092
    [Abstract] [Full Text] [Related]

  • 8. Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb.
    Jaillard S, Larrue B, Deruelle P, Delelis A, Rakza T, Butrous G, Storme L.
    Ann Thorac Surg; 2006 Mar 12; 81(3):935-42. PubMed ID: 16488698
    [Abstract] [Full Text] [Related]

  • 9. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
    Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadaş B, Schermuly RT, Weissmann N, Seeger W, Grimminger F.
    J Am Coll Cardiol; 2004 Oct 06; 44(7):1488-96. PubMed ID: 15464333
    [Abstract] [Full Text] [Related]

  • 10. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides.
    Steiner MK, Preston IR, Klinger JR, Hill NS.
    Curr Opin Pharmacol; 2005 Jun 06; 5(3):245-50. PubMed ID: 15907910
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
    Corbin JD.
    Int J Impot Res; 2004 Jun 06; 16 Suppl 1():S4-7. PubMed ID: 15224127
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.
    Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR.
    Circulation; 2003 Jul 01; 107(25):3230-5. PubMed ID: 12796132
    [Abstract] [Full Text] [Related]

  • 15. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery.
    Pauvert O, Lugnier C, Keravis T, Marthan R, Rousseau E, Savineau JP.
    Br J Pharmacol; 2003 Jun 01; 139(3):513-22. PubMed ID: 12788811
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
    Dunkern TR, Hatzelmann A.
    Cell Signal; 2005 Mar 01; 17(3):331-9. PubMed ID: 15567064
    [Abstract] [Full Text] [Related]

  • 19. Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens.
    Mancina R, Filippi S, Marini M, Morelli A, Vignozzi L, Salonia A, Montorsi F, Mondaini N, Vannelli GB, Donati S, Lotti F, Forti G, Maggi M.
    Mol Hum Reprod; 2005 Feb 01; 11(2):107-15. PubMed ID: 15640438
    [Abstract] [Full Text] [Related]

  • 20. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart.
    Forfia PR, Lee M, Tunin RS, Mahmud M, Champion HC, Kass DA.
    J Am Coll Cardiol; 2007 Mar 13; 49(10):1079-88. PubMed ID: 17349888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.